Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization (original) (raw)

References

  1. Blasi, F. Urokinase and urokinase receptor: a paracrine/autocrine system regulating cell migration and invasiveness. Bioessays 15, 105–111 (1993).
    Article CAS Google Scholar
  2. Mignatti, P. & Rifkin, D.B. Biology and biochemistry of proteinases in tumor invasion. Physiol. Rev. 73, 161–195 (1993).
    Article CAS Google Scholar
  3. Murphy, G., Atkinson, S., Ward, R., Gavrilovic, J. & Reynolds, J.J. The role of plasminogen activators in the regulation of connective tissue metalloproteinases. Ann. NY Acad. Sci. 667, 1–12 (1992).
    Article CAS Google Scholar
  4. Andreasen, P.A., Kjoller, L., Christensen, L. & Duffy, M.J. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int. J. Cancer 72, 1–22 (1997).
    Article CAS Google Scholar
  5. Ossowski, L., Russo-Payne, H. & Wilson E.L. Inhibition of urokinase-type plasminogen activator by antibodies: the effect on dissemination of a human tumor in the nude mouse. Cancer Res. 51, 274–281 (1991).
    CAS PubMed Google Scholar
  6. Yu, H.R. & Schultz, R.M. Relationship between secreted urokinase plasminogen activator activity and metastatic potential in murine B16 cells transfected with human urokinase sense and antisense genes. Cancer Res. 50, 7623–7633 (1990).
    CAS PubMed Google Scholar
  7. Heiss, M.M. et al. Tumor associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system. J. Clin. Oncol. 13, 2084–2093 (1995).
    Article CAS Google Scholar
  8. Pyke, C., Kristensen, P., Ralfkiaer, E., Eriksen, J. & Dano, K. The plasminogen activation system inhuman colon cancer: messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma. Cancer Res. 51, 4067–4071 (1991).
    CAS PubMed Google Scholar
  9. Sier, C.F.M. et al. Inactive urokinase and increased levels of its inhibitor type I in colorectal cancer liver metastasis. Gastroenterology 107, 1449–1456 (1994).
    Article CAS Google Scholar
  10. Liu, G., Shuman, M.A. & Cohen, R.L. Co-expression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells. Int. J. Cancer 60, 501–506 (1995).
    Article CAS Google Scholar
  11. Grondhal-Hansen, J. et al. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res. 53, 2513–2521 (1993).
    Google Scholar
  12. Pedersen, H. et al. Prognostic impact of urokinase, urokinase receptor, and type I plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res. 54, 4671–4675 (1994).
    CAS PubMed Google Scholar
  13. Kuhn, W. et al. Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FICO III) after radical surgery and platinum-based chemotherapy. Gynecol. Oncol. 55, 401–409 (1994).
    Article CAS Google Scholar
  14. Kruithof, E.K., Gudinchet, A. & Bachmann, F. Plasminogen activator inhibitor 1 and plasminogen activator inhibitor 2 in various disease states. Thromb. Haemost. 59, 7–12 (1988).
    Article CAS Google Scholar
  15. Deng, G., Curriden, S.A., Wang, S., Rosenberg, S. & Loskutoff, D.J. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J. Cell Biol. 134, 1–9 (1996).
    Article Google Scholar
  16. Chapman, H.A. Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. Curr. Opin. Cell. Biol. 9, 714–724 (1997).
    Article CAS Google Scholar
  17. Fusenig, N.E., Amer, S.M., Boukamp, P. & Worst, K.M. Characteristics of chemically transformed mouse epidermal cells in vitro and in vivo . Bull. Cancer 65, 271–280 (1978).
    CAS PubMed Google Scholar
  18. Carmeliet, P. et al. Plasminogen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterization. J. Clin. Invest. 92, 2746–2755 (1993).
    Article CAS Google Scholar
  19. Carmeliet, P. et al. Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis. J. Clin. Invest. 92, 2756–2760 (1993).
    Article CAS Google Scholar
  20. DeClerck, P.J., Verstreken, M. & Coolen, D. Immunoassay of murine t-PA, uPA and PAI-1 using monoclonal antibodies raised in gene-inactivated mice. Thomb Haemost. 74, 1305–1309 (1995).
    Article CAS Google Scholar
  21. Lijnen, R.H., Moons, L., Beelen, V., Carmeliet, P. & Collen, D. Biological effects of combined inactivation of plasminogen activator and plasminogen activator inhibitor-1 gene function in mice. Thromb. Haemost. 74, 1126–1131 (1995).
    Article CAS Google Scholar
  22. Nakamura, M. et al. Possible role of plasminogen activator inhibitor 2 in the prevention of the metastasis of gastric cancer tissue. Thromb. Res. 65, 709–719 (1992).
    Article CAS Google Scholar
  23. Nakarda, H. et al. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res. 54, 2900–2907 (1994).
    Google Scholar
  24. Foekens, J.A. et al. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer J. Clin. Oncol. 12, 1648–1658 (1994).
    Article CAS Google Scholar
  25. Skobe, M., Rockwell, P., Goldstein, N., Vosseler, S. & Fusenig, N.E. Halting angiogenesis suppresses carcinoma cell invasion. Nature Med. 3, 1222–1227 (1997).
    Article CAS Google Scholar
  26. Bacharach, E., Itin, A. & Keshet, E. In vivo patterns of urokinase and its inhibitor PAI-1 suggest a concerted role in regulating physiological angiogenesis. Proc. Natl. Acad. Sci. USA 89, 10686–10690 (1992).
    Article CAS Google Scholar
  27. Bianchi, E. et al. Immunohistochemical localization of plasminogen activator inhibitor-1 in breast cancer. Int. J. Cancer 60, 597–603 (1995).
    Article CAS Google Scholar
  28. Schnaper, H.W. et al. Plasminogen activators augment endothelial organization in vitro by two distinct pathways. J. Cell. Physiol. 165, 107–118 (1995).
    Article CAS Google Scholar
  29. Montesano, R. et al. Increased proteolytic activity is responsible for the aberrant morphogenetic behavior of endothelial cells expressing the middle T oncogene. Cell 62, 435–445 (1990).
    Article CAS Google Scholar
  30. Pepper, M.S., Sappino, A.P., Montesano, R., Orci, L. & Vassalli, J.-D. Plasminogen activator inhibitor-1 is induced in migrating endothelial cells. J. Cell. Physiol. 153, 129–139 (1992).
    Article CAS Google Scholar
  31. Kanse, S.M., Kost, C., Wilhelm, O.G., Andreasen, P.A. & Preissner, K.T. The urokinase receptor is a major vitronectin-binding protein on endothelial cells. Exp. Cell Res. 224, 344–353 (1996).
    Article CAS Google Scholar
  32. Stefansson, S. & Lawrence, D.A. The serpin PAI-1 inhibits cell migration by blocking integrin αvβ3 binding to vitronectin. Nature 383, 441–443 (1996).
    Article CAS Google Scholar
  33. Waltz, D.A., Natkin, L.R., Fujita, R.M., Wei, Y. & Chapman, H.A. Plasmin and plasminogen activator type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. J. Clin. Invest. 100, 58–67 (1997).
    Article CAS Google Scholar
  34. Boukamp, P., Stanbridge, E.J., Foo, D.Y., Cerutti, P.A. & Fusenig, N.E. c-Ha-ras oncogene expression in immortalized human keratinocytes (HaCaT) alters growth potential in vivo but lacks correlation with malignancy. Cancer Res. 50, 2840–2847 (1990).
    CAS Google Scholar
  35. Fusenig, N.E. in The Keratinocyte Handbook, (eds. Leigh, I., Lane, B., Watt, F.) 71–49 (Cambridge Univ. Press, Cambridge, 1994).
    Google Scholar
  36. Carmeliet, P., Moons, L., Ploplis, V., Plow, E. & Collen, D. Impaired arterial neointima formation in mice with disruption of the plasminogen gene. J. Clin. Invest. 99, 200–208 (1997).
    Article CAS Google Scholar
  37. Kristensen, P., Pyke, C., Lund, L.R., Andreasen, P.A. & Dano, K. Plasminogen activator inhibitor-type 1 in Lewis lung carcinoma. Histochemistry 93, 559–566 (1990).
    Article CAS Google Scholar
  38. Prendergast, G.C., Diamond, L.E., Dahl, D. &; Cole, M.D. The _c-myc_-regulated gene mrl encodes plasminogen activator inhibitor 1. Mol. Cell. Biol. 10, 1265–1269 (1990).
    Article CAS Google Scholar
  39. Kristensen, P., Eriksen, J., Blasi, F. & Dano, K. Two alternatively spliced mouse urokinase receptor mRNAs with different histological localisation in the gastrointestinal tract. J. Cell Biol. 115, 1763–1771 (1991).
    Article CAS Google Scholar
  40. de Vries, T.J., Kitson, J.L., Silvers, W.K. & Mintz, B. Expression of plasminogen activators and plasminogen activator inhibitors in cutaneous melanomas of transgenic melanoma-susceptible mice. Cancer Res. 55, 4681–4687 (1995).
    CAS PubMed Google Scholar
  41. Sappino, A.P. et al. Differential protease expression by cutaneous squamous and basal cell carcinomas. J. Clin. Invest. 88, 1073–1079 (1991).
    Article CAS Google Scholar
  42. Carmeliet, P. et al. Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation: a gene targeting and gene transfer study in mice. Circulation 96, 3180–3191 (1997).
    Article CAS Google Scholar

Download references